Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Attend scheduled follow-up appointments
Due today: $0 is shown in the footer alongside the Save Credit Card button, and the page copy confirms the card is only charged after a visit has actually been completed
Reluctance or inability to share these details is a significant warning sign
In populations with added comorbidities, results are lower: TRIUMPH-2 (obesity + diabetes) showed 20.8%, TRIUMPH-3 (obesity + cardiovascular disease) showed 22.6%, and TRANSCEND-T2D-1 (diabetes-specific, 40 weeks) showed 16.8% all consistent with patterns seen across the GLP-1 drug class, where comorbidities reduce achievable weight loss
In studies conducted so far, no significant liver-related issues have been reported in individuals using tirzepatide
US$ 28.85
US$ 26.45
US$ 25.99
US$ 23.07
US$ 29.92
